The Global Health Body Sounds Alert Over Severe Scarcity of Obesity Injections

Under 10% of people who could benefit from weight-loss injections including Wegovy can access them, warns the WHO as it issues its initial advice on the drugs.

Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for broader and more equitable access to GLP-1 medication.

Per estimates, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.

"Our new guidelines affirms that excess weight is a chronic disease that can be treated with comprehensive and ongoing care," said WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and logistical bottlenecks are significant barriers to broad availability to the injections that can aid individuals in losing substantial weight, explains the organization.

Weight-Loss Drug Shortage

Even in the current most favorable case, the manufacturing of GLP-1 therapies might only reach around 100 million people – less than 10% of those who need them, according to the health organization.

The recommendation calls on nations and manufacturers to widen availability, via strategies like licensing agreements.

Exclusive production rights on semaglutide – the primary component of a leading brand – is set to lapse in multiple nations in 2026.

How Weight-Loss Drugs Work

These medications mimick a biological compound to slow digestion, reduce hunger and boost the sense of being full so people consume fewer calories.

Individuals usually see weight reduction in the initial weeks of commencing the regular doses.

Studies points to people may see weight return within a year of halting the treatment, because their normal appetite come back.

To be overweight or obese raises your likelihood for experiencing medical conditions, such as diabetes, cardiovascular issues, brain attack, and some cancers.

Excess weight concerns individuals in countries worldwide and was associated with millions of deaths worldwide in 2024, as per the health agency.